C4 Therapeutics, Inc. (Nasdaq: CCCC) presented new biomarker data from two clinical trials of cemsidomide in relapsed/refractory multiple myeloma at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE